Brian F Gage

List of Publications by Citations

Source: https://exaly.com/author-pdf/10240124/brian-f-gage-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130 papers	14,626 citations	48 h-index	120 g-index
138 ext. papers	16,295 ext. citations	7.2 avg, IF	6.13 L-index

#	Paper	IF	Citations
130	Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA - Journal of the American Medical Association*, **2001**, 285, 2864-70	27.4	3578
129	Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. *New England Journal of Medicine*, **2005**, 352, 2285-93	59.2	1149
128	Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). *American Heart Journal*, **2006**, 151, 713-9	4.9	732
127	Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. *Circulation*, **2009**, 119, 1873-82	16.7	701
126	Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. *Circulation*, **2004**, 110, 2287-92	16.7	616
125	Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. *Medical Care*, **2005**, 43, 480-5	3.1	574
124	A pharmacogenetic versus a clinical algorithm for warfarin dosing. *New England Journal of Medicine*, **2013**, 369, 2283-93	59.2	547
123	CYP4F2 genetic variant alters required warfarin dose. *Blood*, **2008**, 111, 4106-12	2.2	428
122	Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. *Blood*, **2010**, 115, 3827-34	2.2	289
121	Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. *Thrombosis and Haemostasis*, **2004**, 91, 87-94	7	282
120	Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). *Journal of the American College of Cardiology*, **2010**, 55, 2804-12	15.1	279
119	Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. *Circulation*, **2011**, 123, 2562-70	16.7	259
118	Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. *Stroke*, **2000**, 31, 822-7	6.7	253
117	Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. *American Journal of Medicine*, **2005**, 118, 612-7	2.4	244
116	Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. *Stroke*, **2006**, 37, 1070-7	6.7	235
115	Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. *Annals of Internal Medicine*, **2009**, 150, 73-83	8	217
114	Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. *Journal of Thrombosis and Thrombolysis*, **2008**, 25, 45-51	5.1	186

113	Cost-effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients With Nonvalvular Atrial Fibrillation. *JAMA - Journal of the American Medical Association*, **1995**, 274, 1839	27.4	182
112	Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. *Thrombosis and Haemostasis*, **2005**, 93, 700-5	7	163
111	Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. *Archives of Internal Medicine*, **2006**, 166, 241-6		162
110	Genetic-based dosing in orthopedic patients beginning warfarin therapy. *Blood*, **2007**, 110, 1511-5	2.2	152
109	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2017**, 318, 1115-1124	27.4	142
108	Management and dosing of warfarin therapy. *American Journal of Medicine*, **2000**, 109, 481-8	2.4	123
107	Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. *Pharmacoepidemiology and Drug Safety*, **2010**, 19, 596-603	2.6	120
106	Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. *JAMA - Journal of the American Medical Association*, **2005**, 293, 699-706	27.4	120
105	Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. *Journal of the American College of Cardiology*, **2018**, 72, 3233-3242	15.1	113
104	High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. *American Heart Journal*, **2013**, 166, 325-332.e1	4.9	112
103	Genetic warfarin dosing: tables versus algorithms. *Journal of the American College of Cardiology*, **2011**, 57, 612-8	15.1	110
102	Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. *Thrombosis and Haemostasis*, **2014**, 111, 88-93	7	98
101	Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. *Stroke*, **1998**, 29, 1083-91	6.7	87
100	The pharmacogenetics of coumarin therapy. *Pharmacogenomics*, **2005**, 6, 503-13	2.6	78
99	Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. *American Journal of Transplantation*, **2004**, 4, 1703-8	8.7	77
98	Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. *Trials*, **2010**, 11, 108	2.8	72
97	Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. *Heart*, **2015**, 101, 1382-8	5.1	68
96	Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke. *Stroke*, **2010**, 41, 1514-20	6.7	67

95	Effect of warfarin nonadherence on control of the International Normalized Ratio. *American Journal of Health-System Pharmacy*, **2004**, 61, 1258-64	2.2	65
94	Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. *Circulation: Heart Failure*, **2016**, 9,	7.6	65
93	Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. *American Journal of Clinical Pathology*, **2008**, 129, 876-83	1.9	63
92	Comorbidity indices to predict mortality from Medicare data: results from the national registry of atrial fibrillation. *Medical Care*, **2005**, 43, 1073-7	3.1	60
91	Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?. *Stroke* , **2007**, 38, 2459-63	6.7	59
90	Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. *Medical Decision Making*, **2005**, 25, 548-59	2.5	57
89	Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. *Thrombosis and Haemostasis*, **2012**, 107, 232-40	7	56
88	Can we rely on RE-LY?. *New England Journal of Medicine*, **2009**, 361, 1200-2	59.2	56
87	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. *American Journal of Hematology*, **2019**, 94, 1176-1184	7.1	53
86	Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. *American Heart Journal*, **2003**, 146, 286-90	4.9	53
85	Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. *Thrombosis Research*, **2015**, 135, 616-20	8.2	49
84	Pharmacogenetics-based coumarin therapy. *Hematology American Society of Hematology Education Program*, **2006**, 2006, 467-73	3.1	48
83	Reliability for grading acute rejection and airway inflammation after lung transplantation. *Journal of Heart and Lung Transplantation*, **2005**, 24, 652-7	5.8	48
82	The impact of the introduction of a rapid D-dimer assay on the diagnostic evaluation of suspected pulmonary embolism. *Archives of Internal Medicine*, **2001**, 161, 567-71		48
81	Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. *Circulation*, **2012**, 125, 2353-62	16.7	47
80	Gamma-glutamyl carboxylase and its influence on warfarin dose. *Thrombosis and Haemostasis*, **2010** , 104, 750-4	7	46
79	Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 840-847	7.3	46
78	Genotype and risk of major bleeding during warfarin treatment. *Pharmacogenomics*, **2014**, 15, 1973-83	2.6	45

77	Statins Are Associated With Reduced Mortality in Multiple Myeloma. *Journal of Clinical Oncology*, **2016**, 34, 4008-4014	2.2	43
76	A Tool to Assess Risk of De Novo Opioid Abuse or Dependence. *American Journal of Medicine*, **2016**, 129, 699-705.e4	2.4	43
75	Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. *Journal of Arthroplasty*, **2017**, 32, 645-652	4.4	43
74	Physician and nurse acceptance of technicians to screen for geriatric syndromes in the emergency department. *Western Journal of Emergency Medicine*, **2011**, 12, 489-95	3.3	42
73	Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. *Journal of Heart and Lung Transplantation*, **2004**, 23, 1396-404	5.8	41
72	Warfarin therapy for an octogenarian who has atrial fibrillation. *Annals of Internal Medicine*, **2001**, 134, 465-74	8	40
71	Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. *Clinical Chemistry*, **2009**, 55, 1861-8	5.5	38
70	Incidence of Platelet Dysfunction by Thromboelastography-Platelet Mapping in Children Supported with ECMO: A Pilot Retrospective Study. *Frontiers in Pediatrics*, **2015**, 3, 116	3.4	38
69	Patient and physician satisfaction with a telephone-based anticoagulation service. *Journal of General Internal Medicine*, **2001**, 16, 460-3	4	37
68	Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP. *Anesthesia and Analgesia*, **2017**, 124, 398-405	3.9	36
67	Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. *Thrombosis Research*, **2014**, 133, 25-9	8.2	34
66	Criteria for outpatient management of proximal lower extremity deep venous thrombosis. *Chest*, **1999**, 115, 972-9	5.3	34
65	Influence of nitrous oxide anesthesia, B-vitamins, and MTHFR gene polymorphisms on perioperative cardiac events: the vitamins in nitrous oxide (VINO) randomized trial. *Anesthesiology*, **2013**, 119, 19-28	4.3	31
64	Risk model for estimating the 1-year risk of deferred lesion intervention following deferred revascularization after fractional flow reserve assessment. *European Heart Journal*, **2015**, 36, 509-15	9.5	27
63	Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. *Chest*, **2003**, 123, 499-503	5.3	27
62	Substitution of generic warfarin for Coumadin in an HMO setting. *Annals of Pharmacotherapy*, **2002**, 36, 764-8	2.9	26
61	Effectiveness and safety of expanded perioperative thromboprophylaxis in complex gynecologic surgery. *Gynecologic Oncology*, **2015**, 138, 501-6	4.9	25
60	Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. *American Heart Journal*, **2009**, 157, 1057-63	4.9	24

59	Optimal initial dose adjustment of warfarin in orthopedic patients. *Annals of Pharmacotherapy*, **2007**, 41, 1798-804	2.9	23
58	Pharmacogenetics and anticoagulant therapy. *Journal of Thrombosis and Thrombolysis*, **2003**, 16, 73-8	5.1	22
57	The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. *American Journal of Medicine*, **2004**, 116, 451-9	2.4	22
56	Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. *American Journal of Kidney Diseases*, **2005**, 46, 791-8	7.4	22
55	Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. *JACC: Heart Failure*, **2015**, 3, 146-53	7.9	19
54	Cost-savings analysis of using a portable coagulometer for monitoring homebound elderly patients taking warfarin. *The American Journal of Geriatric Cardiology*, **2003**, 12, 283-7		18
53	Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. *Heart Rhythm*, **2005**, 2, 367-73	6.7	17
52	Establishing and running an effective telephone-based anticoagulation service. *Journal of Vascular Nursing*, **2001**, 19, 126-32; quiz 133-4	1	16
51	High-Sensitivity Cardiac Troponin T Improves the Diagnosis of Perioperative MI. *Anesthesia and Analgesia*, **2017**, 125, 1455-1462	3.9	15
50	Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. *Circulation*, **2012**, 125, 1414-23	16.7	14
49	Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. *Thrombosis Research*, **2005**, 117, 55-9; discussion 65-7	8.2	14
48	Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. *American Heart Journal*, **2013**, 166, 435-41	4.9	13
47	Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. *Thrombosis Research*, **2020**, 185, 125-131	8.2	11
46	Pediatric warfarin practice and pharmacogenetic testing. *Thrombosis Research*, **2010**, 126, e144-6	8.2	9
45	Outpatient treatment of acute venous thromboembolic disease. *Clinics in Chest Medicine*, **2003**, 24, 49-61	5.3	9
44	Factors Associated With Clinical Deterioration Among Patients Hospitalized on the Wards at a Tertiary Cancer Hospital. *Journal of Oncology Practice*, **2019**, 15, e652-e665	3.1	9
43	Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment. *American Journal of Transplantation*, **2020**, 20, 250-261	8.7	9
42	Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. *Journal of General Internal Medicine*, **2015**, 30, 777-82	4	8

41	Anemia does not predict mortality in elderly patients with heart failure. *The American Journal of Geriatric Cardiology*, **2007**, 16, 92-6		8
40	The Association of Fever and Antipyretic Medication With Outcomes in Mechanically Ventilated Patients: A Cohort Study. *Shock*, **2019**, 52, 152-159	3.4	8
39	Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries. *Pharmacoepidemiology and Drug Safety*, **2019**, 28, 951-964	2.6	6
38	Is primary care ready for pharmacogenetics?. *Pharmacogenomics*, **2006**, 7, 1-3	2.6	6
37	Use of pharmacogenetics to guide warfarin therapy. *Drugs of Today*, **2004**, 40, 247-57		6
36	Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis. *International Journal for Vitamin and Nutrition Research*, **2020**, 90, 42-48	1.7	6
35	Accuracy of Wearable Cameras to Track Social Interactions in Stroke Survivors. *Journal of Stroke and Cerebrovascular Diseases*, **2016**, 25, 2907-2910	2.8	6
34	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2019**, 322, 834-842	27.4	5
33	A systematic analysis and comparison of warfarin initiation strategies. *Pharmacogenetics and Genomics*, **2016**, 26, 445-52	1.9	5
32	Perioperative reduction of the warfarin dose. *American Journal of Medicine*, **2003**, 115, 741-2	2.4	5
31	Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System. *American Heart Journal*, **2016**, 179, 186-91	4.9	5
30	TEG Platelet Mapping and Impedance Aggregometry to Predict Platelet Transfusion During Cardiopulmonary Bypass in Pediatric Patients. *Frontiers in Pediatrics*, **2019**, 7, 509	3.4	5
29	Predictors of long-term opioid use and opioid use disorder among construction workers: Analysis of claims data. *American Journal of Industrial Medicine*, **2021**, 64, 48-57	2.7	4
28	Venous thromboembolism in multiple myeloma is associated with increased mortality. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 1203-1210	5.1	3
27	Couma-Gen: implications for future randomized trials of pharmacogenetic-based warfarin therapy. *Personalized Medicine*, **2008**, 5, 163-168	2.2	3
26	Postoperative Myocardial Injury and Inflammation Is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients. *HSS Journal*, **2018**, 14, 67-76	2	2
25	An invasive strategy is associated with decreased mortality in patients 80 years and older with acute myocardial infarction. *The American Journal of Geriatric Cardiology*, **2007**, 16, 84-91		2
24	Randomized trial of warfarin nomograms. *Annals of Internal Medicine*, **2004**, 140, 489; author reply 491-28		2

23	Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index. *Journal of Visualized Experiments*, **2020**,	1.6	2
22	Clinical Benefit of American College of Chest Physicians Versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. *Journal of General Internal Medicine*, **2015**, 30, 1405	4	1
21	The analysis of bleeding risk-prediction scores should include all major bleeds. *Journal of the American College of Cardiology*, **2013**, 61, 481-482	15.1	1
20	Interview about the GIFT Trial, Pharmacogenetics, and Warfarin. *Pharmacogenomics*, **2017**, 18, 1379-1380	2.6	1
19	Seasonal control of warfarin therapy. *American Journal of Medicine*, **2001**, 111, 332	2.4	1
18	Venous Thromboembolism Is Associated with Increased Mortality in Patients with Multiple Myeloma. *Blood*, **2014**, 124, 2176-2176	2.2	1
17	Predictive value of the present-on-admission indicator for hospital-associated hemorrhage. *Thrombosis Research*, **2019**, 180, 20-24	8.2	0
16	Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, e937-e943	2	0
15	Improving Follow-up Attendance for Discharged Emergency Care Patients Using Automated Phone System to Self-schedule: A Randomized Controlled Trial. *Academic Emergency Medicine*, **2021**, 28, 197-205	3.4	0
14	Reply to S. Suissa et al. *Journal of Clinical Oncology*, **2017**, 35, 1378-1379	2.2	
13	The Reply. *American Journal of Medicine*, **2017**, 130, e115	2.4	
12	Reply: Coronary Artery Calcium Screening in the Young and Other Responses: The Walter Reed Cohort. *Journal of the American College of Cardiology*, **2019**, 73, 1873-1874	15.1	
11	Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events-Reply. *JAMA - Journal of the American Medical Association*, **2018**, 319, 1279-1280	27.4	
10	In reply. *Anesthesiology*, **2014**, 120, 515-6	4.3	
9	Letter in response to "Use of preoperative cardiac troponin T to identify patients at risk for acute myocardial infraction and long-term mortality after major noncardiac surgery". *American Heart Journal*, **2014**, 167, e7	4.9	
8	Top practice-changing articles over the last two years. *Journal of Thrombosis and Thrombolysis*, **2013**, 35, 325-32	5.1	
7	The Association of Warfarin Use With Osteoporotic Fracture in Elderly Patients With Atrial Fibrillation: Reply. *Archives of Internal Medicine*, **2006**, 166, 1525		
6	Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure. *American Journal of Cardiology*, **2005**, 95, 286-8	3	

5	Metformin Therapy and Survival in Multiple Myeloma Among US Veterans with Diabetes Mellitus. *Blood*, **2015**, 126, 4502-4502	2.2
4	Statin Therapy Improves Multiple Myeloma (MM) Specific Surviva. *Blood*, **2015**, 126, 879-879	2.2
3	Application of a Validated Predictive Model for Venous Thromboembolism in Cancer to Patients with Multiple Myeloma. *Blood*, **2016**, 128, 534-534	2.2
2	Risk Factors for Inpatient Acute Venous Thromboembolism (VTE) Despite Thromboprophylaxis.. *Blood*, **2012**, 120, 2248-2248	2.2
1	Higher Doses of Prophylactic Anticoagulation Is More Effective in Preventing Venous Thromboembolism in Morbidly Obese Inpatients.. *Blood*, **2012**, 120, 2268-2268	2.2